Andrea Carpaneto

Risk stratification for <scp>S</scp>plenic <scp>M</scp>arginal <scp>Z</scp>one <scp>L</scp>ymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases

Carlos Montalbán, Víctor Abraira, Luca Arcaini et al. · British Journal of Haematology · 2012 · 91 citations · Full text

Medicine, Biostatistics, Oncology +13

Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin’s lymphoma patients

Luigi Rigacci, Benedetta Puccini, Sergio Cortelazzo et al. · Annals of Hematology · 2012 · 38 citations

Medicine, Oncology, Pharmacotherapy +7

18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: Long-term results

Luigi Rigacci, Antonio Castagnoli, Catia Dini et al. · Oncology Reports · 2005 · 35 citations

Medicine, Oncology, Radiology +14

Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after ⁹⁰Y‐ibritumomab‐tiuxetan

Francesco Cicone, Eleonora Russo, Andrea Carpaneto et al. · Hematological Oncology · 2010 · 10 citations

Medicine, Nuclear Medicine, Oncology +16

Sequential Brief Chemo-Immunotherapy FND + Rituximab in Elderly Patients with Advanced Stage Follicular Lymphoma (FL): High Clinical and Molecular Remission Rate Associated with a Prolonged Failure-Free Survival.

Umberto Vitolo, Carola Boccomini, Marco Ladetto et al. · Blood · 2004 · 10 citations

Medicine, Immunology, Oncology +10